anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In order to make up for the vacancy of the prior art, the invention provides a Yi medicine for acute stage of gout, which comprises the following components in parts by mass: rhizoma Smilacis Glabrae, rhizoma Atractylodis preparata, cortex Phellodendri, Bulbus Lilii, semen plantaginis, rhizoma Dioscoreae Septemlobae, cortex Nothapodytis Radicis, YUNFILING, cacumen Securinegae Suffruticosae, and Curcumae rhizoma processed with vinegar. The preparation method of the medicine comprises the following steps: s1, preparing the dry medicinal herbs according to the formula amount for later use. S2, adding the prepared medicinal herbs into water for decoction, carrying out solid-liquid separation after the decoction is finished, and taking liquid-phase components to obtain a liquid medicine A. And S3, filtering and concentrating the liquid medicine A, and then carrying out spray drying to obtain paste powder. Crushing and sieving the paste powder to obtain medicinal powder A. And S4, adding dextrin into the medicinal powder A, uniformly mixing, and performing dry granulation to obtain the Yi medicine for treating acute gout. The medicine is prepared by adopting the compatibility of Yi specific medicines, and has remarkable curative effect. And can obviously alleviate the gastrointestinal reaction of the patient during the administration period and obviously improve the compliance of the patient.
Will not actively suction carbon dioxide from abdomen. Open laparoscopic trocars and allow C02 to passively empty from abdomen.
The invention discloses an isocoumarin compound, and a preparation method and application thereof. The isocoumarin compound takes aspergillus fungi aspergillus oryzae obtained from paris polyphylla var. yunnanensis as basis, and is obtained through strain isolation, strain culture, large-scale fermentation, organic-solvent extraction, normal- and reverse-phase silica gel column chromatography enrichment and high pressure liquid chromatography separation, possesses the molecular formula of C16H18O5, and is named oryzaeins B, and the structural formula is shown in the specification. The preparation method comprises taking aspergillus fungi aspergillus oryzae obtained from paris polyphylla var. yunnanensis as basis and processing through steps of strain isolation, strain culture, large-scale fermentation, organic-solvent extraction, normal- and reverse-phase silica gel column chromatography enrichment and high pressure liquid chromatography separation. The application concretely means application of the isocoumarin compound to prepare anti-rotavirus medicaments. The compound is simple in structure and relatively good in activity, and can be used as an anti-rotavirus medicament research and development pilot compound applied to research and development of anti-rotavirus medicament preparations.
PURPOSE:To prepare a drug for human Mycoplasma infection, containing MFX as an active component, and effective even to a microbial strain resistant to macrolide antibiotic substances. CONSTITUTION:The objective drug contains MFX {9-fluoro-2,3-dihydro-methyl-10- (4-methyl-1-piperadinyl)-7-oxo-7H-pyrido [1, 2, 3-de] -1, 4-benzoxazine-6-carboxylic acid} as an active component. Tetracycline and macrolide antibiotic substances are usually used for the remedy of Mycoplasma infection; however, the frequency of developing a strain resistant to macrolide antibiotic substances especially erythromycin, etc. is high, and the infection with the resistant strain has become impossible by the use of said antibiotic substances. The MFX enables the remedy of the infection with the resistant strain. It is useful for the remedy of human Mycoplasma infection (e.g. atypical pneumonia, encephalomeningitis, etc.).
PURPOSE: To enable healing of a wound such as skin ulcer, by using polysaccharide chitosan for application to a wound. CONSTITUTION: Chitosan is used at the ultimate concentration effective to accelerate healing and/or to suppress growth of germs. Preferably it is used as the ultimate concentration of about 0.1 to about 10% (weight percent based on the weight) of the composition). Especially preferable is the chitosan concentration of about 0.5 to about 5%. The composition also includes at least one kind of compatible hydrocolloid material other than chitosan. The preferable hydrocolloid material is one that can be directly mixed with chitosan in the solution, namely, the one whic is colligated easily with chitosan in the aqueous solution and forms a composition which does not receive syneresis.
Much effort has been made to uncover the cellular heterogeneities of human hearts by single-nucleus RNA sequencing. However, the cardiac transcriptional regulation networks have not been systematically described because of the limitations in detecting transcription factors. In this study, we optimized a pipeline for isolating nuclei and conducting single-nucleus RNA sequencing targeted to detect a higher number of cell signal genes and an optimal number of transcription factors. With this unbiased protocol, we characterized the cellular composition of healthy human hearts and investigated the transcriptional regulation networks involved in determining the cellular identities and functions of the main cardiac cell subtypes. Particularly in fibroblasts, a novel regulator, PKNOX2, was identified as being associated with physiological fibroblast activation in healthy hearts. To validate the roles of these transcription factors in maintaining homeostasis, we used single-nucleus RNA-sequencing analysis of transplanted failing hearts focusing on fibroblast remodelling. The trajectory analysis suggested that PKNOX2 was abnormally decreased from fibroblast activation to pathological myofibroblast formation. Both gain- and loss-of-function in vitro experiments demonstrated the inhibitory role of PKNOX2 in pathological fibrosis remodelling. Moreover, fibroblast-specific overexpression and knockout of PKNOX2 in a heart failure mouse model induced by transverse aortic constriction surgery significantly improved and aggravated myocardial fibrosis, respectively. In summary, this study established a high-quality pipeline for single-nucleus RNA-sequencing analysis of heart muscle. With this optimized protocol, we described the transcriptional regulation networks of the main cardiac cell subtypes and identified PKNOX2 as a novel regulator in suppressing fibrosis and a potential therapeutic target for future translational studies.
mTOR inhibitors (mTOR-Is) may induce proteinuria in kidney transplant recipients through podocyte damage. However, the mechanism has only been partially defined. Total cell lysates and supernatants of immortalized human podocytes treated with different doses of everolimus (EVE) (10, 100, 200, and 500 nM) for 24 h were subjected to mass spectrometry-based proteomics. Support vector machine and partial least squares discriminant analysis were used for data analysis. The results were validated in urine samples from 28 kidney transplant recipients receiving EVE as part of their immunosuppressive therapy. We identified more than 7000 differentially expressed proteins involved in several pathways, including kinases, cell cycle regulation, epithelial-mesenchymal transition, and protein synthesis, according to gene ontology. Among these, after statistical analysis, 65 showed an expression level significantly and directly correlated with EVE dosage. Polo-Like Kinase 1 (PLK1) content was increased, whereas osteopontin (SPP1) content was reduced in podocytes and supernatants in a dose-dependent manner and significantly correlated with EVE dose (p < 0.0001, FDR < 5%). Similar results were obtained in the urine of kidney transplant patients. This study analyzed the impact of different doses of mTOR-Is on podocytes, helping to understand not only the biological basis of their therapeutic effects but also the possible mechanisms underlying proteinuria.
FIELD: genetic engineering of viruses. SUBSTANCE: invention proposes viral vector coated with membrane that encodes transmembrane protein comprising deletions by one or more amino acids. Viral vector is able to infect insect cells and to be replicated in them but unable to replicate in mammalian cells. Viral vector is useful for producing viral vaccine. EFFECT: valuable biological properties of vector. 9 cl, 5 dwg, 2 tbl, 8 ex
OBJECTIVE: Severe traumatic brain injury (TBI) is a public health issue posing significant morbidity and mortality to afflicted patients. While the effect of time to surgery as the primary factor for survival has been extensively studied, long-term dispositional outcomes following intracranial hemorrhage evacuation have not been well described in the literature. Therefore, the aim of this study was to elicit potential prognostic factors in patients presenting with severe TBI that may have a significant impact on discharge disposition.
METHODS: The authors searched the National Trauma Data Bank (NTDB) for patients included between 2010 and 2019, solely focusing on those with a Glasgow Coma Scale score ≤ 8, signifying severe TBI, and with associated intracranial hemorrhage treated via surgical intervention. Numerous characteristics were analyzed, including demographics (age, sex, race, ethnicity, payment status), discharge disposition, time to surgery, pupillary response, midline shift (> 5 mm), and postoperative inpatient complications and comorbidities. Disposition included routine discharge to home, discharge to home with home health services (HHSs), discharge to acute inpatient rehabilitation (AIR), discharge to a skilled nursing facility (SNF)/long-term acute care hospital (LTACH), and death.
RESULTS: The authors analyzed data on 7308 patients, 69.6% of whom were White and 11.2% of whom were Black. More young Black and Hispanic patients had severe TBI events than their matched elders, whereas more elderly White patients had severe TBI events than their matched younger counterparts. The most common disposition across all ages was SNF/LTACH. Septuagenarians and octogenarians were 12.1 and 21 times more likely, respectively, to die following a severe TBI than their younger counterparts (p < 0.001). Patients aged 18-29 were 1.7 times more likely to be discharged with HHSs (p < 0.001). Minority race/ethnicity groups were less likely to be discharged to AIR. As age increased, a patient's intensive care unit stay increased by 15 days (p < 0.001) and total hospital length of stay increased by 25 days (p < 0.001).
CONCLUSIONS: Neurosurgical evacuation of intracranial hemorrhage in severe TBI has variable long-term morbidity. Utilizing the largest collection of trauma data within the United States, the authors present quantitative evidence on discharge disposition. Understanding these tangible points can help neurosurgeons present potential outcomes to patients, promote preventative care, and generate tangible conversations with patients and their family members.
PURPOSE:To provide a composition for suppressing the formation of sordes on tooth, having excellent caries-preventing effect and producible economically on an industrial scale, by using a specific amount of one or more components selected from water-soluble chitin and chitosan as active components. CONSTITUTION:The crust of e.g. crab, lobster, krill, etc. is crushed, treated with hydrochloric acid to remove calcium carbonate, treated with caustic soda to remove proteins and other impurities, washed with water, and dried to obtain chitin and chitosan (a deacetylated product of chitin) having white flaky form. The product is depolymerized by decomposition to obtain water-soluble chitin or chitosan. At least one kind of compound selected from the above compounds is added in an amount of 1ppm-10wt%, preferably 1ppm-0.5wt% to obtain the objective composition for suppressing the formation of sordes on tooth. EFFECT:The adsorption of Streptococcus mutans which is a kind of oral streptococci causing dental caries can be inhibited and the S. mutans adsorbed on the surface of the teeth is desorbed.
This study is an extension of an ongoing clinical trial (ClinicalTrials.gov identifier NCT 00308997) that was initiated in 2006. The primary objective of the ongoing clinical trial (hereafter called the "parent trial") is to determine efficacy of rTMS in curbing auditory hallucinations when delivered to a part of the left temporal lobe called Wernicke's area and a corresponding region in the right temporal lobe. The parent trial appears to show robust effects for active rTMS compared to effects of sham stimulation. However, observed responses following active rTMS have often been incomplete. Moreover, in some cases there has been a subsequent return of symptoms 1 to 6 months after the trial ended.

We consequently have initiated a trial where patients who have participated in the parent trial and demonstrated an incomplete response or a subsequent return of symptoms may return to receive additional active rTMS. We hypothesize that efficacy of suppressive rTMS will be enhanced if directed simultaneously to right/left Wernicke's area (the site used in the parent trial) as well as to a second site located in the opposite middle temporal cortex. Roughly half of subjects in the re-enrollment will be randomized to receive active rTMS to right/left Wernicke's area plus active rTMS to opposite hemisphere middle temporal region, while half of subjects will be randomized to receive active rTMS to right/left Wernicke's area plus sham rTMS to opposite hemisphere middle temporal region. The position of the middle temporal regions will be determined by two recently completed brain imaging studies of auditory hallucinations suggesting that activation in these sites triggers auditory hallucinations. The two-position design will allow us to determine if active rTMS delivered to the middle temporal cortex is superior in amplifying efficacy of active rTMS targeting Wernicke's area and in reducing auditory hallucinations to sham stimulation to the same site. The re-enrollment protocol will utilize two rTMS devices simultaneously where one directly triggers the other.

This study record has been amended to remove a third arm that was added in 2012. The third arm described was not actually a comparative arm, but rather an added objective with a different study population. Dr. Ralph Hoffman unexpectedly passed away while this study was being conducted. This study has been submitted as a separate study (NCT04548622) where the summarized study results of the terminated study will be presented.
Independent risk factors for sepsis-associated acute kidney injury (S-AKI) patients include elevated lactate levels, but the specific mechanism remains unclear. Recently, An et al. discovered that excessive acetylation and inactivation of PDHA1 lead to overproduction of lactate, resulting in mitochondrial fragmentation, ATP depletion, excessive mtROS production, and mitochondrial apoptosis, thereby exacerbating AKI in sepsis. Therefore, understanding the pathophysiological processes of mitochondrial function and lactate generation in SAKI is essential and can aid in the development of novel therapeutic strategies. This review elucidates the pathological mechanisms of mitochondrial autophagy and dynamics in AKI. We also discuss the sources of lactate in SAKI and some consequences of lactonization, which may provide new strategies for improving renal injury and delaying the progression of these diseases.
The present invention provides novel, long-acting nanoformulated drugs and targeted drug delivery methods, and uses thereof. In one embodiment, the nanoformulated drug is a retroviral drug. In one embodiment, the nanoformulated composition comprises a nanocarrier with one or more incorporated drugs. In an exemplary embodiment, the drug is efavirenz (EFV). In a further embodiment, the nanocarrier is associated with an agent for targeting microfold cells (M-cells). In a specific embodiment, the targeting agent binds to an M-cell marker known as glycoprotein 2 (GP2). Via this mechanism, the nanodrug is targeted toward GALT.
The most efficient emission spectrum of light for phototherapy is blue-green light emission diode light with peak emission at 478 nm. In the irradiance interval of phototherapy, the relationship between efficacy and irradiance is almost linear, and it is negatively related to the haemoglobin. The action sites of phototherapy are the extravascular compartment and cutaneous blood. The most immature neonates treated aggressively had not only a lower frequency of neurodevelopmental impairment than conservatively treated, but also greater mortality. Intermittent and continuous phototherapy are assumed to be equally efficient. Home-based fibreoptic phototherapy is effective and safe. Important progress is still occurring in phototherapy.
An antifungal peptide targeting P4-ATPase function is synthesized based on Cdc50 loop region to identify peptides sensitize caspofungin by blocking flippase function. It was found that myristylated peptides based on “AS15 sequence” was effective at high concentrations. A modified peptide, “AW9-Ma” showed minimum inhibitory concentration (MIC) of 64 μg/mL against H99 wild type and fractional inhibitory concentration (FIC) index value of 0.5 when used with caspofungin. With the AW9-Ma peptide,  C. neoformans  wild type was highly sensitive to caspofungin with a MIC of 4 μg/mL, the same as cdc50Δ mutant. Further assays with flow cytometry showed inhibition of lipid flippase enzyme activity and significant accumulation of phosphatidylserine on the cell surface. It was confirmed that the peptide co-localized with mCherry-tagged P4-ATPase protein Apt1 in  C. neoformans . Modification studies of AW9 sequence showed that two lysine residues on the peptide are likely responsible for interaction with P4-ATPasee critical for antifungal activity.
To enhance user experience and improve patient workflow, data collection and patient imaging protocols are monitored, and real-time notifications are triggered, generated, and provided to end users (e.g. Radiologists, Technologists, service personnel, hospital management, etc.) autonomously, remotely, and in real-time, when a customizable condition is met such as when a scan protocol is finished and reconstructed successfully. The notifications are sent from a scanner host computer or an analysis system and received via email, instant message, etc., and can be pulled into an independent mobile application. Progress indicators are provided, which facilitate informing an attending physician of a predicted scan completion time so that the physician can prepare (e.g. get to the reading room, scanner room, log into mobile reviewing device, etc.) to review the scan results immediately. The user can choose to see aborted, finished, or in-progress scans for any patient, patient group, medical device, or any selected hospital.
Individuals included in this group will receive 20 minutes of action observation training in addition to 40 minutes of standard rehabilitation. Patients will be trained 3 days a week for 6 weeks.
Subjects who will receive placebo in the double-blinded period; when assigned to receive the placebo during the double-blinded period, subjects will be given a sugar pill for 8 weeks. The sugar pill will be taken twice per day, at 8am and 12pm.
The utility model relates to an immunomoduling synbiotic composition, in particular a probiotic bacterial composition additionally enriched with a prebiotic and biologically active substances influencing beneficially the human health in prophylaxis and/or therapy of inflammatory and immune diseases of the gastrointestinal tract, including symptoms of intestinal dysbiosis and irritable bowel syndrome. In particular, the composition comprises a probiotic component of living cells of a biologically pure culture of the bacterial strains of Lactobacillus delbrueckii subsp. bulgaricus LLB-06 – (НБПМКК) NBPMKK 8918, Lactobacillus helveticus LLH-108 - (НБПМКК) NBPMKK 8760, Lactobacillus acidophilus LLA-10 - (НБПМКК) NBPMKK 8242, Lactobacillus rhamnosus LLR-L1 - (НБПМКК) NBPMKK 8769 and Lactobacillus fermentum LLF-01 - (НБПМКК) NBPMKK 8781, prebiotic - Arabinogalactan and Colostrum. The used strains of lactic acid bacteria are selected so that in combination with each other and with the other components, prebiotics and colostrum, have high survival rate and achieve the specific probiotic effect and guaranteed antimicrobial activity against human pathogens, as well as the adhesion and immunomodulating properties of the composition. The indigestible dietary plant fibers of arabinogalactan due to its immunomodulatory (antiviral and anti-tumor) activity combined with the synbiotic formula form a protective layer around the probiotics and control their release into the intestinal tract. The enriched multifunctional formula of the synbiotic composition according to the utility model, including proline-rich polypeptides (4.5%) and IgG (at least 20%) colostrum, delivers the necessary immune, growth factors and a balanced combination of vitamins and minerals.
Diaphragmatic hernias arising from trauma are rare, and scarcely present in a delayed manner. This case report highlights a case of delayed presentation of a right-sided post-traumatic hernia in a woman in her early 70s following a fall. The aim of this report is to shed light on the diagnostic peculiarities and management. The woman presented with a 3-day history of abdominal pain and coffee-ground vomiting. This followed a fall a month ago. CT confirmed the diagnosis of a gastric outlet obstruction secondary to a right-sided diaphragmatic rupture. At surgery, the herniated abdominal contents were reduced, and the diaphragmatic defect was fixed. The postoperative recovery was unremarkable, and the patient was discharged on day 4. This case highlights that diaphragmatic hernias should be considered as differential diagnoses following recent trauma.
The present invention relates to a method of diagnosing cancer, precancerous state, and susceptibility to other forms of diseases, by use of a molecular marker, interferon-regulatory factor-1 (IRF-1). The method is characterized in that IRF-1-specific RNA is analysed in a sample obtained from blood or other biopsy material, preferably by reverse transcription/polymerase chain reaction. The invention is based on the unexpected finding that a novel mechanism of inactivation of the tumor suppressor gene IRF-1 plays a crucial role e.g. in hematopoietic malignancies. An unusual exon skipping leads to RNA molecules which lack exon 2 or exons 2 and 3. The relative amounts of full-length RNA and shortened RNA molecules are significantly different in samples obtained from tumor patients as compared to healthy donors. <IMAGE>
The safety, tolerability, and pharmacokinetic profile of PTI-428 will be evaluated following a single dose of PTI-428. Three cohorts are planned for evaluation where subjects will be randomized to PTI-428 or placebo.The subjects will be followed for 7 days post dose.